Clinical Trials on Stage IV Osteosarcoma AJCC v7 in Netherlands

Total 36 results

Maastricht Radiation Oncology
Amsterdam UMC, location VUmc

Completed

Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients (Cetuximab Zr89)

Stage IV Cancer

Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Chordoma | Rhabdomyosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Untreated Childhood Rhabdomyosarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 and other conditions

United States, Netherlands, Canada, Australia, New Zealand, Puerto Rico, Switzerland
The Netherlands Cancer Institute
Bristol-Myers Squibb

Terminated

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

NSCLC, Stage IV

Netherlands
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Uterine Corpus Leiomyosarcoma | Stage I Uterine Sarcoma AJCC v7

United States, Belgium, France, Spain, United Kingdom, Netherlands, Norway, Venezuela
The Netherlands Cancer Institute

Recruiting

FMT to Convert Response to Immunotherapy

Melanoma Stage IV | Melanoma Stage III

Netherlands
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
Maastricht Radiation Oncology
Karolinska Institutet; KU Leuven; Maastricht University Medical Center; Catholic... and other collaborators

Withdrawn

Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) (ImmunoSABR)

NSCLC Stage IV | Limited Metastatic Disease

Netherlands
Radboud University Medical Center
Maastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaborators

Recruiting

PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer (PROMOTE)

Endometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IV

Netherlands
Erasmus Medical Center

Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Immunotherapy | Melanoma Stage IV | Melanoma Stage III | Toxicity, Drug

Netherlands
The Netherlands Cancer Institute

Unknown

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (TCR)

Stage IV Skin Melanoma | Eye; Melanoma

Netherlands
Maastricht Radiation Oncology

Not yet recruiting

Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer (Re-Induce 2)

Lung Cancer Stage IV

Netherlands
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
Radboud University Medical Center
Dutch Cancer Society

Completed

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

Melanoma Stage III or IV

Netherlands
Radboud University Medical Center
Dutch Cancer Society

Completed

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

Melanoma Stage III or IV

Netherlands
Maastricht University Medical Center
KU Leuven; University College, London; Erasmus Medical Center; Catholic University... and other collaborators

Active, not recruiting

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (IMMUNOSABR2)

NSCLC Stage IV | Metastatic Disease

Netherlands, Belgium, United Kingdom, Germany, France, Italy
Amsterdam UMC, location VUmc

Completed

Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT) (COLONUT)

Stage IV Colorectal Cancer

Netherlands
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NSCLC Stage IV

Netherlands
Maastricht University Medical Center
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

NSCLC Stage IV | Brain Metastases, Adult

Netherlands
Maastricht Radiation Oncology

Completed

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Stage IV (Oligo-metastases)

Netherlands
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
Immutep S.A.S.

Completed

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Adenocarcinoma Breast Stage IV

Netherlands, United Kingdom, France, Belgium, Germany, Hungary, Poland
Maastricht Radiation Oncology
Maastricht University Medical Center; Zuyderland Medical Centre

Completed

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Stage IV Non-small Cell Lung Cancer

Netherlands
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Cancer Stage IV

Netherlands
Saint John's Cancer Institute
Melanoma Research Alliance

Terminated

Stage IV Surgery Versus Best Medical Therapy (STG4SURG)

Stage IV Resectable Melanoma

United States, Australia, Israel, Italy, Netherlands
UMC Utrecht
Center for Translational Molecular Medicine; Dutch Cancer Society; Vrienden UMC...

Recruiting

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (i-GO)

Breast Cancer | Breast Neoplasms | Metastatic Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Invasive Ductal Breast Cancer | Invasive Ductal Carcinoma of Female Breast | Adenocarcinoma Breast

Netherlands
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
ETOP IBCSG Partners Foundation
AstraZeneca

Recruiting

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)

Non-small Cell Lung Cancer | Oligometastasis | Stage IV

Switzerland, Netherlands, Spain, Italy
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
G1 Therapeutics, Inc.

Completed

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Stage IV Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female

United States, Belgium, Bulgaria, Georgia, Netherlands, Moldova, Republic of, Ukraine
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain

Clinical Trials on Stage IV Osteosarcoma AJCC v7 in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations